Erythremia (Polycythemia Vera) – A Complete Patient‑Friendly Guide

Overview

Erythremia, more commonly known as Polycythemia Vera (PV), is a chronic myeloproliferative neoplasm in which the bone marrow produces too many red blood cells (RBCs). The excess RBCs increase blood volume and viscosity, predisposing the patient to clotting and a range of systemic symptoms.

Who it affects

• Typical onset: 50–70 years of age.
• ~60 % of patients are male, but women are also affected.
• Incidence: about 1–2 cases per 100,000 persons per year in the United States and Europe.^CDC
• Higher prevalence in people of Northern European ancestry.

Symptoms

Symptoms arise from both the elevated red‑cell mass (hyperviscosity) and the associated increase in platelets and white blood cells. The presentation is often subtle and may be mistaken for normal aging.

Common (≥30 % of patients)

• Headache and dizziness – due to reduced cerebral blood flow.
• Pruritus after a warm bath or shower – histamine release from increased basophils.
• Reddened complexion (plethora) – especially facial flushing.
• Fatigue and weakness – paradoxically despite higher RBC count.
• Blurred vision or visual disturbances – from retinal micro‑vascular congestion.

Less common but clinically important

• Unexplained weight loss.
• Night sweats.
• Gout attacks – from elevated uric acid.
• Edema of the ankles.
• Bleeding tendencies (e.g., nosebleeds, bruising) due to platelet dysfunction.
• Fullness or a feeling of “pressure” in the head after standing.

Symptoms that suggest disease progression

• Sudden chest pain or shortness of breath – possible pulmonary embolism.
• Sudden weakness or numbness on one side – stroke.
• Unexplained fevers or night sweats – possible transformation to myelofibrosis or acute leukemia.

Causes and Risk Factors

PV is not caused by lifestyle choices; it is a clonal stem‑cell disorder.

Genetic mutation

• >95 % of cases harbor the JAK2 V617F mutation, which leads to constitutive activation of the JAK‑STAT pathway and uncontrolled blood cell production.^{NEJM, 2005}
• Rarely, other mutations (JAK2 exon 12, MPL, CALR) are identified.

Risk factors

• Age > 50 years.
• Male sex.
• Family history of myeloproliferative neoplasms (first‑degree relative).
• Exposure to ionizing radiation (e.g., prior therapeutic radiation).
• Long‑standing chronic inflammation may modestly increase risk, though data are limited.

Diagnosis

Diagnosing PV requires a combination of clinical findings, laboratory tests, and bone‑marrow evaluation. The 2016 World Health Organization (WHO) criteria are widely used.

Step‑by‑step approach

1. Complete blood count (CBC) – Hemoglobin > 16.5 g/dL (men) or > 16.0 g/dL (women), hematocrit > 49 % (men) or > 48 % (women), and elevated RBC mass.
2. Serum erythropoietin (EPO) level – Typically low or undetectable in PV because the marrow is autonomous.
3. JAK2 mutation testing – PCR or next‑generation sequencing for V617F or exon‑12 mutations.
4. Bone‑marrow biopsy – Hypercellular marrow with pan‑myelosis (increased red cells, white cells, and megakaryocytes) without significant fibrosis.
5. Red‑cell mass measurement – Radioisotope (e.g., 51Cr) or calculated from CBC and plasma volume; confirms absolute erythrocytosis.

Supporting tests

• Serum uric acid – often elevated.
• Liver function tests – to rule out secondary causes.
• Coagulation profile – baseline before antiplatelet therapy.
• Imaging (e.g., Doppler ultrasound) – if thrombosis is suspected.

Treatment Options

The goals of therapy are to reduce blood viscosity, prevent thrombosis, control symptoms, and limit disease progression.

Phlebotomy (Therapeutic Venesection)

• First‑line for most patients.
• Target hematocrit < 45 % (< 42 % in high‑risk patients) – a level shown to reduce cardiovascular events (CYTO-PV trial).^{NEJM, 2014}
• Typically 500 mL removed weekly until target is reached, then spaced out to every 2–3 months for maintenance.

Low‑dose Aspirin

• 81 mg daily reduces arterial thrombosis risk without significantly increasing bleeding.^{Cleveland Clinic}

Myelosuppressive agents (for high‑risk or phlebotomy‑refractory patients)

• Hydroxyurea – First‑line cytoreductive drug; dose titrated to maintain hematocrit < 45 %.
• Interferon‑α (pegylated) – Preferred for younger patients or those desiring pregnancy; can induce molecular remission.
• Ruxolitinib – JAK1/2 inhibitor approved for patients resistant or intolerant to hydroxyurea; improves splenomegaly and symptom burden.

Other supportive measures

• Hydration – helps keep blood less viscous.
• Management of pruritus – antihistamines, selective serotonin reuptake inhibitors, or low‑dose aspirin.
• Control of cardiovascular risk factors – blood pressure, cholesterol, diabetes.

Living with Erythremia (Polycythemia Vera)

PV is a chronic condition, but with appropriate management most patients lead active lives.

Daily management tips

• Stay hydrated – Aim for ≥ 2 L of water daily unless otherwise instructed.
• Monitor hematocrit – Keep a log of lab results; discuss trends with your hematologist.
• Regular phlebotomy appointments – Treat them like routine blood work.
• Exercise safely – Low‑impact activities (walking, swimming) improve circulation; avoid extreme dehydration or high‑altitude sports without physician clearance.
• Avoid smoking – Smoking increases viscosity and thrombosis risk.
• Set reminders for medication – Use phone alarms or pill organizers.
• Watch for symptom changes – New headaches, chest pain, or leg swelling should be reported promptly.

Psychosocial considerations

• Join support groups (e.g., MPN Voice, local patient advocacy organizations).
• Consider counseling if anxiety about chronic disease becomes overwhelming.
• Inform family members about signs of thrombosis and when to call for help.

Prevention

Because PV originates from a genetic mutation, primary prevention is not possible. However, secondary prevention—reducing complications—is achievable.

• Control modifiable cardiovascular risk factors (hypertension, hyperlipidemia, diabetes).
• Maintain target hematocrit through scheduled phlebotomy.
• Take low‑dose aspirin unless contraindicated.
• Stay current with vaccinations (influenza, COVID‑19, pneumococcal) to lower infection‑related inflammation.

Complications

If left inadequately treated, PV can lead to serious health issues.

• Thrombosis – Deep‑vein thrombosis, pulmonary embolism, stroke, myocardial infarction; the leading cause of morbidity.
• Hemorrhage – Paradoxical bleeding due to platelet dysfunction.
• Myelofibrosis transformation – ~5‑10 % progress to post‑polycythemic myelofibrosis, causing severe anemia and splenomegaly.
• Acute myeloid leukemia (AML) – 2‑5 % risk, higher after prolonged hydroxyurea exposure.
• Gout – Elevated uric acid from rapid cell turnover.
• Pregnancy complications – Increased miscarriage, pre‑eclampsia, and placental insufficiency if disease is uncontrolled.

When to Seek Emergency Care

References

• World Health Organization. Myeloproliferative Neoplasms – Revised Criteria. 2016.
• Vannucchi AM, et al. “Polycythemia Vera.” New England Journal of Medicine. 2014;371:2273‑2283. doi:10.1056/NEJMra1406113
• Tefferi A. “Polycythemia Vera and Essential Thrombocythemia: 2023 Update on Diagnosis, Risk‑Stratification, and Management.” Blood. 2023;141(7):712‑730.
• Barbui T, et al. “Cytoreductive Therapy in Polycythemia Vera: Rationale and Evidence.” American Journal of Hematology. 2022;97(12):1487‑1499.
• Centers for Disease Control and Prevention. “Incidence of Myeloproliferative Neoplasms.” 2021. CDC
• Mayo Clinic. “Polycythemia Vera – Symptoms and causes.” 2024. Mayo Clinic
• Cleveland Clinic. “Aspirin Therapy for Polycythemia Vera.” 2023. Cleveland Clinic